{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:18:53Z","timestamp":1772165933225,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T00:00:00Z","timestamp":1672963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015083","name":"Peking University People's Hospital","doi-asserted-by":"publisher","award":["RDY 2021-21"],"award-info":[{"award-number":["RDY 2021-21"]}],"id":[{"id":"10.13039\/501100015083","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Health Technologies Promotion Program","award":["BHTPP2022082"],"award-info":[{"award-number":["BHTPP2022082"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To establish a prognostic nomogram among UTUC patients who received chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>1195 UTUC patients who received chemotherapy were extracted from the Surveillance, Epidemiology, and End Results (SEER) database for the period between 2004 and 2015. Patients were randomly divided into a training and a validation set. Nomogram was constructed to predict 1-, 3-, and 5-year overall survival (OS) in those patients. Receiver-operating characteristic curves (ROCs), calibration plots, and Decision curve analysis (DCA) were applied to assess and compare the discrimination, accuracy, and practicability of the nomogram with 8th American Joint Committee on Cancer (AJCC) tumor node metastasis (TNM) staging system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six clinical parameters were identified as independent prognostic factors for UTUC patients\u2019 OS, including age, marital status, TNM stage, and surgical methods of the primary site. The ROC curves showed a satisfactory discrimination capacity of the nomogram, with 1-, 3-, and 5-year area under curve (AUC) values of 0.789, 0.772, and 0.763 in the training set and 0.772, 0.822, and 0.814 in the validation set, respectively. Calibration curves indicated a good agreement between actual observation and nomogram prediction. ROC and DCA curves showed our nomograms exhibited larger benefits than the 8th AJCC-TNM staging system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A prognostic nomogram was established and validated to present individual predictions of OS among chemotherapeutic UTUC patients. This nomogram may assist clinicians in accurate survival prognostication, treatment decision-making, and design of future clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12894-022-01172-8","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T12:02:57Z","timestamp":1673006577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic nomogram for overall survival in upper urinary tract urothelial carcinoma (UTUC) patients treated with chemotherapy: a SEER-based retrospective cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Cong","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizhe","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingquan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"issue":"1","key":"1172_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA A Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA A Cancer J Clin"},{"issue":"7","key":"1172_CR2","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/j.1464-410X.2010.09675.x","volume":"107","author":"JD Raman","year":"2011","unstructured":"Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973\u20132005. BJU Int. 2011;107(7):1059\u201364.","journal-title":"BJU Int"},{"issue":"3","key":"1172_CR3","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00345-016-1928-x","volume":"35","author":"F Soria","year":"2017","unstructured":"Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, Lotan Y, Ye D, Fern\u00e1ndez MI, et al. Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol. 2017;35(3):379\u201387.","journal-title":"World J Urol"},{"issue":"4","key":"1172_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00345-010-0594-7","volume":"29","author":"SF Shariat","year":"2011","unstructured":"Shariat SF, Favaretto RL, Gupta A, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Tritschler S, Baba S, Matsushita K, et al. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol. 2011;29(4):481\u20136.","journal-title":"World J Urol"},{"issue":"7","key":"1172_CR5","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/jso.25877","volume":"121","author":"G Rosiello","year":"2020","unstructured":"Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, Deuker M, Mistretta FA, Tian Z, Fossati N, Gallina A, et al. Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. J Surg Oncol. 2020;121(7):1154\u201361.","journal-title":"J Surg Oncol"},{"key":"1172_CR6","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam, 2022. ISBN 978-94-92671-16-5"},{"issue":"5","key":"1172_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.eururo.2020.07.003","volume":"79","author":"JJ Leow","year":"2021","unstructured":"Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol. 2021;79(5):635\u201354.","journal-title":"Eur Urol"},{"key":"1172_CR8","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.urology.2019.01.058","volume":"129","author":"X Meng","year":"2019","unstructured":"Meng X, Chao B, Vijay V, Silver H, Margolin EJ, Balar A, Taneja SS, Shah O, Bjurlin MA, Anderson CB, et al. High response rates to neoadjuvant chemotherapy in high-grade upper tract urothelial carcinoma. Urology. 2019;129:146\u201352.","journal-title":"Urology"},{"issue":"10232","key":"1172_CR9","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto JWF, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet (London, England). 2020;395(10232):1268\u201377.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"1172_CR10","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1016\/j.clgc.2018.02.005","volume":"16","author":"O Abdel-Rahman","year":"2018","unstructured":"Abdel-Rahman O. Revisiting the prognostic heterogeneity of AJCC stage IV carcinomas of the upper urinary tract. Clin Genitourin Cancer. 2018;16(4):e859\u201365.","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"1172_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00345-016-1826-2","volume":"35","author":"A Mbeutcha","year":"2017","unstructured":"Mbeutcha A, Roupr\u00eat M, Kamat AM, Karakiewicz PI, Lawrentschuk N, Novara G, Raman JD, Seitz C, Xylinas E, Shariat SF. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol. 2017;35(3):337\u201353.","journal-title":"World J Urol"},{"issue":"8","key":"1172_CR12","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","volume":"26","author":"A Iasonos","year":"2008","unstructured":"Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364\u201370.","journal-title":"J Clin Oncol"},{"issue":"27","key":"1172_CR13","doi-asserted-by":"publisher","first-page":"18797","DOI":"10.18632\/oncotarget.24694","volume":"9","author":"H Goldberg","year":"2018","unstructured":"Goldberg H, Klaassen Z, Chandrasekar T, Sayyid R, Kulkarni GS, Hamilton RJ, Fleshner NE. Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. Oncotarget. 2018;9(27):18797\u2013810.","journal-title":"Oncotarget"},{"key":"1172_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fonc.2020.00481","volume":"10","author":"TS Zhai","year":"2020","unstructured":"Zhai TS, Jin L, Feng LM, Zhou Z, Liu X, Liu H, Ma WG, Lu JY, Chen W, Yao XD, et al. Perioperative chemotherapy on survival in patients with upper urinary tract urothelial carcinoma undergoing nephroureterectomy: a population-based study. Front Oncol. 2020;10:481.","journal-title":"Front Oncol"},{"issue":"1","key":"1172_CR15","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1186\/s12885-021-08742-3","volume":"21","author":"M Wang","year":"2021","unstructured":"Wang M, Ren X, Wang G, Sun X, Tang S, Zhang B, Xing X, Zhang W, Gao G, Du J, et al. Construction of a survival prediction model for high-and low-grade UTUC after tumor resection based on \u201cSEER database\u201d: a multicenter study. BMC Cancer. 2021;21(1):999.","journal-title":"BMC Cancer"},{"issue":"4","key":"1172_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","volume":"58","author":"MG Kaag","year":"2010","unstructured":"Kaag MG, O\u2019Malley RL, O\u2019Malley P, Godoy G, Chen M, Smaldone MC, Hrebinko RL, Raman JD, Bochner B, Dalbagni G, et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol. 2010;58(4):581\u20137.","journal-title":"Eur Urol"},{"issue":"5","key":"1172_CR17","first-page":"607","volume":"21","author":"J Wu","year":"2021","unstructured":"Wu J, Chen S, Wu X, Mao W, Wang Y, Xu B, Zheng D, Chen M. Trends of incidence and prognosis of upper tract urothelial carcinoma. Bosn J Basic Med Sci. 2021;21(5):607\u201319.","journal-title":"Bosn J Basic Med Sci"},{"issue":"3","key":"1172_CR18","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.21037\/tau.2020.03.28","volume":"9","author":"F Qi","year":"2020","unstructured":"Qi F, Wei X, Zheng Y, Sha Y, Lu Y, Li X. Nomograms to predict overall and cancer-specific survival in patients with upper tract urothelial carcinoma: a large population-based study. Transl Androl Urol. 2020;9(3):1177\u201391.","journal-title":"Transl Androl Urol"},{"issue":"4 Pt 1","key":"1172_CR19","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1097\/01.ju.0000137910.38441.8a","volume":"172","author":"B Czito","year":"2004","unstructured":"Czito B, Zietman A, Kaufman D, Skowronski U, Shipley W. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol. 2004;172(4 Pt 1):1271\u20135.","journal-title":"J Urol"},{"issue":"3","key":"1172_CR20","doi-asserted-by":"publisher","first-page":"790","DOI":"10.7150\/jca.50419","volume":"12","author":"Z Li","year":"2021","unstructured":"Li Z, Li X, Li Y, Liu Y, Du P, Liu Z, Xiao K. A novel nomogram for predicting the survival of patients with invasive upper tract urothelial carcinoma. J Cancer. 2021;12(3):790\u20138.","journal-title":"J Cancer"},{"issue":"7","key":"1172_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048243","volume":"11","author":"C Li","year":"2021","unstructured":"Li C, Han D, Huang Q, Xu F, Zheng S, Li X, Zhao F, Feng X, Lyu J. Competing-risks nomogram for predicting cancer-specific death in upper tract urothelial carcinoma: a population-based analysis. BMJ Open. 2021;11(7): e048243.","journal-title":"BMJ Open"},{"issue":"1","key":"1172_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4081\/aiua.2022.1.7","volume":"94","author":"Y Al Salhi","year":"2022","unstructured":"Al Salhi Y, Fuschi A, Martoccia A, Velotti G, Suraci PP, Scalzo S, Rera OA, Antonioni A, Valenzi FM, Bozzini G, et al. Laparoscopic radical nephroureterectomy with only three trocars: results of a prospective single centre study. Arch Ital Urol Androl. 2022;94(1):7\u201311.","journal-title":"Arch Ital Urol Androl"},{"issue":"5","key":"1172_CR23","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/bju.14751","volume":"124","author":"S Zamboni","year":"2019","unstructured":"Zamboni S, Foerster B, Abufaraj M, Seisen T, Roupret M, Colin P, De la Taille A, Di Bona C, Peyronnet B, Bensalah K, et al. Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. BJU Int. 2019;124(5):738\u201345.","journal-title":"BJU Int"},{"issue":"6","key":"1172_CR24","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1097\/JU.0000000000000523","volume":"203","author":"K Mori","year":"2020","unstructured":"Mori K, Janisch F, Parizi MK, Mostafaei H, Lysenko I, Kimura S, Enikeev DV, Egawa S, Shariat SF. Prognostic value of variant histology in upper tract urothelial carcinoma treated with nephroureterectomy: a systematic review and meta-analysis. J Urol. 2020;203(6):1075\u201384.","journal-title":"J Urol"},{"issue":"9","key":"1172_CR25","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s00345-019-03003-2","volume":"38","author":"KH Tully","year":"2020","unstructured":"Tully KH, Krimphove Md MJ, Huynh MJ, Marchese M, Kibel AS, Noldus J, Kluth LA, McGregor B, Chang SL, Trinh QD, et al. Differences in survival and impact of adjuvant chemotherapy in patients with variant histology of tumors of the renal pelvis. World J Urol. 2020;38(9):2227\u201336.","journal-title":"World J Urol"},{"issue":"1","key":"1172_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s00345-012-0877-2","volume":"31","author":"M Cosentino","year":"2013","unstructured":"Cosentino M, Palou J, Gaya JM, Breda A, Rodriguez-Faba O, Villavicencio-Mavrich H. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol. 2013;31(1):141\u20135.","journal-title":"World J Urol"},{"issue":"5","key":"1172_CR27","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.eururo.2012.02.042","volume":"61","author":"E Xylinas","year":"2012","unstructured":"Xylinas E, Rink M, Margulis V, Karakiewicz P, Novara G, Shariat SF. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol. 2012;61(5):1069\u201370.","journal-title":"Eur Urol"}],"updated-by":[{"DOI":"10.1186\/s12894-023-01231-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000}}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-022-01172-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-022-01172-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-022-01172-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T08:05:07Z","timestamp":1687593907000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-022-01172-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,6]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1172"],"URL":"https:\/\/doi.org\/10.1186\/s12894-022-01172-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2150556\/v1","asserted-by":"object"}]},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,6]]},"assertion":[{"value":"10 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12894-023-01231-8","URL":"https:\/\/doi.org\/10.1186\/s12894-023-01231-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SEER is a publicly available database. No ethical approval or informed consent was required to access the data. The study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Cong Tian and Jun Liu declare conflict of interest that they contributed equally to this work. Remaining all authors (Yang Hong, Lizhe An, and Qingquan Xu) declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}